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Both normal antithrombin-III (AT-IIIa) and the high heparin affinity form (AT-III/?) were isolated from 
pooled human plasma. AT-III/l had a lower negative charge and lower molecular mass than AT-IIIa. Siali- 
dase and endo-F digestion indicated that the inherent difference resided in the oligosaccharide component 
of the molecule. CNBr fragmentation showed there was an oligosaccharide sidechain missing between resi- 
dues 104 and 251, subdigestion with trypsin indicated that Asn 135 was not glycosylated in AT-III/X Chro- 
matography of total tryptic digests on concanavalin A-Sepharose confirmed that the high heparin affinity 
form of antithrombin lacked an oligosaccharide moiety at Asn 135. 
Antithrombin-III; Physiological variant; Carbohydrate attachment; Asparagine; (Human) 
1. INTRODUCTION 
Antithrombin-III (AT-III, molecular mass 58 
kDa) is the prime plasma inhibitor of the serine 
proteases involved in the final steps of the coagula- 
tion pathway. Its rate of inhibition of thrombin 
and factor Xa are greatly increased through in- 
teraction with heparin [1,2]. Two forms of anti- 
thrombin-III (cu and ,8) exist in normal plasma [3], 
the predominant species, AT-IIIa, has four bi- 
antennary oligosaccharide sidechains attached at 
asparagines 96, 135, 155 and 172 [4]. The minor 
species, AT-III,8, is present as 5-10% of the total 
antithrombin [3]. It has a lower apparent mole- 
cular mass and higher heparin affinity than AT- 
111~~ and, in addition, contains a lesser proportion 
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of constituent monosaccharide units [3]. 
We show here that AT-III,8 has an apparently 
normal primary sequence, but lacks an oligosac- 
charide sidechain at asparagine 135. 
2. MATERIALS AND METHODS 
2.1. Materials 
Sialidase Type VI (C. perfringens) was obtained 
from Sigma. Endo-fi-N-acetylglucosaminidase-F 
(endo-F, F. meningosepticum) was obtained from 
New England Nuclear. 
2.2. Fractionation of antithrombin 
AT-III,& was isolated from an unused trailing 
fraction in the commercial production of AT-III 
on heparin-Agarose during elution with 2 M NaCl 
[5,6]. This material, enriched in high heparin af- 
finity antithrombin, was re-chromatographed on a 
2.5 x 30 cm column of heparin-Sepharose and 
eluted with a linear gradient of 0.4 to 1.5 M NaCl 
in 20 mM Tris-HCl, pH 7.5 [7], to give two frac- 
tions containing AT-IIIcr and AT-IIZa, respective- 
ly. 
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2.3. Isolation of CNBr fragments 
Twelve mg of each antithrombin species was car- 
boxyamidomethylated [8] and cleaved with CNBr 
[9]. Digests were redissolved in 0.8 ml 6 M urea/ 
2% SDS and applied to separate preparative SDS 
polyacrylamide slab gels (12.5%). Bands were 
visualised by staining with 0.25 M KC1 [lo] and 
were eluted by diffusion in water. Peptides were 
recovered by precipitation with four volumes of 
acetone (- 20°C). 
2.4. Peptide mapping 
Tryptic digestion was carried out as described by 
Brennan [l l] and two-dimensional peptide map- 
ping was performed on Whatman no. 1 paper with 
electrophoresis at pH 6.5 and chromatography in 
the upper phase of pyridine/isoamyl alcohol/water 
(6:6:7) [12]. Maps were stained with 0.002% 
fluorescamide. Mobilities and molecular masses 
were calculated as described by Offord [13]. 
2.5. Glycopeptide isolation 
Eight mg of carboxyamidomethylated anti-anti- 
thrombin was digested with trypsin. Digests were 
chromatographed on a 1.5 x 9 cm column of con- 
canavalin A-Sepharose in 20 mM NHdHCOj, 20 
PM with respect to Mg’+, Ca*+ and Mn’+. Un- 
bound peptides were collected directly in this buf- 
fer while bound peptides were eluted with 25 mM 
methyl-a-D-glucoside/20 mM NHdHCO3 and col- 
klected in a minimal volume. 
2.6. Structural studies 
Peptides were hydrolysed (110°C for 16 h) under 
vacuum, using vapour from 6 M HCl/ 1 Vo phenol 
[ 141. Hydrolysates were coupled with phenyliso- 
thiocyanate and the phenylthiocarbamyl deriva- 
tives of the amino acids were quantified by reverse- 
phase HPLC using a Waters Nova pat column 
[ 121. Peptides were sequenced by a manual micro 
Edman technique [ 12,151. PTH amino acids were 
identified by reverse-phase chromatography on a 
Waters Nova pat column [12]. 
3. RESULTS 
3.1. Preliminary characterisation 
AT-1110 was eluted from the heparin-Sepharose 
column at 0.8 M NaCl. AT-IIIP had a higher 
heparin affinity eluting at I .2 M NaCl, it also had 
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a lower net negative charge as demonstrated by its 
electrophoretic mobility (fig.1, lanes 2 and 3). In- 
cubation with sialidase abolished the charge dif- 
ference between the two forms of antithrombin 
(fig. 1) suggesting that their inherent difference 
resided in their carbohydrate structure rather than 
in their amino acid sequence. AT-III@ had a lower 
apparent molecular mass than AT-I& (fig.2, 
lanes 2 and 1). As expected the molecular mass of 
both proteins decreased on sialidase treatment, but 
the molecular mass difference between them was 
retained (fig.2). 
On incubation with endo-F which cleaves the 
oligosaccharide component to leave a single as- 
paragine-linked N-acetylglucosamine residue, 
most (70%) of the AT-I& was converted to a 
band of similar molecular mass to native AT-HIP, 
with apparently one carbohydrate sidechain miss- 
ing (fig.2, lane 7). AT-III@, on the other hand, was 
comparatively unaffected by endo-F. Both an- 
tithrombins showed additional minor lower M, 
bands, the result of more extensive removal of car- 
bohydrate sidechains (fig.2, lanes 7 and 8). 
3.2. Mapping of CNBr fragments 
CNBr digests of AT-III@ showed the expected 
Fig. 1. Agarose gel electrophoresis pH 8.6 showing effect 
of sialidase on AT-III fractions. (1) Plasma control. (2) 
Purified AT-III~u. (3) Purified AT-III,8. (4 and 5) AT- 
111~~ and AT-III@, respectively, after 2 h incubation with 
neuraminidase (6 and 7). Antithrombins LY and ,8, 
respectively, after 20 h incubation. Antithrombin (1 
mg/ml) was incubated (ZO’C) with 5% w/w sialidase in 
50 mM acetate buffer pH 5.5/S mM CaCl2. 
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Fig.2. SDS-polyacrylamide gel (10%) electrophoresis 
showing effects of sialidase and endo-F (1 and 3). AT- 
111~~ before and after 2 h incubation with sialidase (2 and 
4). AT-III@ before and after sialidase treatment (5 and 
7). AT-IIIa before and after endo-F treatment (6 and 8). 
AT-III,& before and after endo-F treatment. Two ~1 of 
endo-F was added to 0.1 mg of antithrombin in 100 pl 
of 0.1 M phosphate buffer pH 6.1/50 mM EDTA/l% 
NP-40/0.1% SDS and incubated for 24 h at 20°C. 
large 25 kDa fragment. This was missing from 
digests of AT-IIl,f3 and replaced by a smaller 22 500 
kDa peptide (fig.3, lanes 4 and 5). These peptides, 
designated CNU 25 kDa and CNB 22.5 kDa, 
respectively, were purified by preparative SDS 
acrylamide gel electrophoresis (fig.3, lanes 8 and 
9). Amino acid analysis showed that they had 
essentially the same composition and that they cor- 
responded to the expected CNBr peptide encom- 
passing residues 104-25 1. This was substantiated 
when both peptides were found to have the N- 
terminal sequence of Glu-Val-Phe-Lys-Phe-Asp-. 
The C-terminal tryptic peptide (below) of CN,& 
22.5 kDa was also normal, with a composition of 
Ala, Asp, Gly, Glu, Ser, Cys, Ser, Ala, Ser, 
homoserine. This region of the molecule (104-25 1) 
contains three of the four expected oligosaccharide 
sidechains and the molecular mass difference be- 
tween the peptides (2500) is accountable for by the 
loss of just one of these sidechains. 
When peptides CNcv 25 kDa and CNP 22.5 kDa 
were digested with trypsin no significant dif- 
ferences were discernible on reverse phase HPLC 
mapping [ 111. Two-dimensional mapping, how- 
ever, showed that CNcv 25 kDa contained a single 
1 
Fig.3. SDS-polyacrylamide gradient gel (lo-20%) of 
CNBr fragments. (1) Native AT-IIIcy. (2) Native AT- 
III@. (3) Marker, partial acid hydrolysis of 
carboxyamidomethylated (CM@ human albumin, major 
bands at 25, 48 and 68 kDa. (4) CNBr digest of CMn 
AT-IIIa. (5) CNBr digest of CMn AT-IIU. (6 and 7) 
Acetone precipitates of 4 and 5, respectively. (8) Purified 
peptide CN~Y 25 kDa. (9) Purified abnormal peptide 
CNfl 22.5 kDa. (10) Purified CNBr peptide 
corresponding to antithrombin residues 339-423. (11) 
Red cell Iysate containing markers of carbonic 
anhydrase (29 kDa) and LY- (15.5 kDa) and P-globin 
(16 kDa). 
neutral peptide (TraO) that was missing from 
digests of CNP 22.5 kDa (fig.4). PTH analysis of 
Tr& gave a sequence of Lys-Ala-Asn*-Lys and 
established that it was the expected glycopeptide 
originating from cleavage at Arg 132 and Lys 136. 
Peptide TrcvO is confirmed as a glycopeptide by its 
observed neutral electrophoretic mobility, the 
negative charges of the two sialic acid residues be- 
ing balanced by the positive charges on its two 
lysines. Fig.4 shows that this peptide is replaced by 
two basic peptides (Trfil and Tr,&2) in digests of 
CNp 22.5 kDa. Peptide TrPl had a composition of 
Lys, Ala, Asn, Lys and a pH 6.5 mobility of 0.85. 
This is in keeping with a predicted mobility of 0.84 
for a peptide with a residue weight of 459 and a 
charge of + 2 [13]. Peptide Tr,&2 had a composi- 
433 
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Fig.4. 
which 
tion ( zrf Ala, Asn, Lys and a predicted mobility of 
0.50, the mobility of such a peptide (residue weight 
331, charge + 1) being 0.54. 
An rino acid analysis was performed on all major 
Tryptic peptide maps of purified CNBr peptides. CNlv 25 kDa (upper map) contains a neutral peptide ‘I 
is missing in digests of CNP 22.5 kDa (lower map) and replaced by two new basic peptides Tr/31 and 1 
Electrophoresis pH 6.5. 
tryptic peptides from CNp22.5 kDa and each cor- 
responded to tryptic peptides expected to o ccur 
between methionines 103 and 251. In partict .dar, 
peptides on the N- and C-terminal sides of > ‘r,81 
‘rcu0, 
Yr,82. 
434 
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Fig.5. Tryptic peptide maps of peptides isolated by chromatography on concanaval in A-Sepharose. (A) Unbound 
fraction from AT-IIIa (upper) and AT-III,!? (lower). (B) Bound peptides from AT-IIIa (upper) and AT-IIU (lower). 
Cathode at left. 
were normal, with compositions of Leu, Tyr, Arg confirmed that they were not glycosylated. The 
and Ser, Ser, Lys, respectively. Peptide Tr@3 was glycopeptide fraction that bound to the concan- 
in the same position in both maps (fig.3) and its avalin A was eluted with methyl cr-glucoside. Pep- 
composition matched that of the expected tryptic tide maps of this fraction (fig.SB) indicated that 
glycopeptide, residues 15 1- 169. Overstaining for AT-III& possessed a single neutral glycopeptide 
tryptophan located the third glycopeptide, though TraO which was missing in the case of AT-III,&. 
it was not possible to analyse this peptide, it oc- The sequence of TraO was again established as 
cupied the same position in both cases. Lys-Ala-Asn*-Lys. 
3.3. Isolation of glycopeptides 
Tryptic digests of carboxyaminomethylated AT- 
IIIa and AT-III@ were chromatographed on con- 
canavalin A-Sepharose. In each case, the unbound 
peptides were collected and mapped (fig.SA). In 
the case of AT-IIW, the two new basic peptides 
Tr,&l, and TrP2 were observed and, as before, 
these had compositions of Lys, Ala, Asn, Lys and 
Ala, Asn, Lys, respectively. Their electrophoretic 
mobilities and direct elution from concanavalin A 
This, therefore, confirms the earlier data and 
establishes that the differences between AT-IIIa 
and AT-III.8 are due to the lack of an oligosac- 
charide sidechain on asparagine 135 in AT-III,8. 
4. DISCUSSION 
The initial observation in this investigation was 
that a minor component (some 5%) of circulating 
antithrombin possessed a higher heparin affinity. 
Peterson and Blackburn [3] showed that this, AT- 
435 
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III,8, had a lower molecular mass than AT-111~ 
and that it contained 2%30% less hexosamine, 
neutral sugars and sialic acid. In this investigation 
we have established that this difference is due to 
the lack of one of the four oligosaccharide side- 
chains. 
The absence of carbohydrate at Asn 135 is in 
keeping with the observed increase in affinity for 
heparin. The tertiary structure of antithrombin can 
be modelled from homology with the known struc- 
ture of cui-antitrypsin [ 16,171. This model shows an 
area of positive charge formed by Lys 125, Arg 129 
and Arg 132 on the D helix and Arg 47 on the A 
helix. This last residue is known to be essential for 
heparin binding [ 17,181, and the grouping of basic 
residues almost certainly forms an anionic site for 
the binding of the polysulphonated heparin mole- 
cule. The oligosaccharide at Asn 135 is immediate- 
ly distal to the D helix in a site where its bulk 
presumably limits access to the adjacent heparin 
binding site. Thus absence of the oligosaccharide 
in antithrombin ,B results in a predictable increase 
in heparin affinity. 
Plasminogen is another plasma glycoprotein 
that displays variation in its oligosaccharide con- 
tent, with a concomitant alteration in its binding to 
an affinity resin (Sepharose-lysine) [19]. The high 
affinity form of plasminogen lacks a complex 
oligosaccharide at asparagine residue 238. The 
favoured explanation for its absence is that the 
oligosaccharide precursor was not transferred 
from the dolichol precursor to the plasminogen 
during synthesis, rather than removal of the 
oligosaccharide in the circulatory system. It is not 
clear which of these explanations applies to the 
AT-III,& however, treatment of AT-IIIa with 
endo-F shows that AT-III@ has one oligosac- 
charide that is readily removed. AT-III,&, on the 
other hand, is comparatively unaffected by this en- 
zyme, the implication being that antithrombin 
possesses one labile oligosaccharide which could 
potentially be removed in circulation. 
The physiological significance of the circulatory 
removal (or failure of attachment) of the oligosac- 
charide is not clear, but potentially, it provides 
another level of control on coagulation by altering 
the avidity of antithrombin for thrombin when 
heparin activation is suboptimal. 
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